Evofem Biosciences Inc. has reported its financial results for the second quarter of 2025, revealing an increase in net sales to $4.8 million, up from $4.2 million in the same period last year. The company also showed an improvement in its loss from operations, which decreased to $1.3 million from $1.4 million in the prior year quarter. However, the net loss attributable to common stockholders was $1.8 million, compared to a net income of $1.3 million in the second quarter of 2024. Evofem's CEO, Saundra Pelletier, expressed optimism about future sales, attributing anticipated growth to upcoming social media initiatives and positive press coverage for PHEXXI. The company continues to implement fiscal austerity measures but remains confident in its strategic direction. Total operating expenses for the quarter rose to $6.1 million from $5.5 million in the previous year, influenced by increased selling and marketing expenses, partially due to the Prescription Drug User Fee Act (PDUFA) fee for SOLOSEC, and higher R&D expenses related to the same acquisition. Despite these increases, general and administrative expenses saw a decrease of $0.4 million.